Sabirnetug
Monoclonal antibody
Also known as ACU193
Evidence outlook · program status
Discontinued (2026-10), after a negative readout
Acumen stopped development of sabirnetug after the Phase 2 ALTITUDE-AD trial missed its primary endpoint (30 October 2026). The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
Company guidance: topline data expected November 2026 (NCT06335173; Acumen Pharmaceuticals, 26 Oct 2026). “The Company is currently focused on advancing a targeted immunotherapy drug candidate, sabirnetug, in its Phase 2 ALTITUDE-AD clinical trial, and plans to announce top-line results in November 2026.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ALTITUDE-AD NCT06335173 · Alzheimer Disease Caveat: this result is taken from a company announcement, not from the trial registry or a peer-reviewed publication. Registry: NCT06335173 | 2 | Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score (Baseline up to Week 80) 2026-10-29 | Primary endpoint, change from baseline in iADRS at 18 months: not met (Acumen Pharmaceuticals, 2026-10-30). | not yet graded | link ↗ |
View 1 more trial
INTERCEPT-AD NCT04931459 · Alzheimer Disease This randomized, double-blind, placebo-controlled first-in-human study gave single or multiple intravenous doses of sabirnetug or placebo to 65 people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The primary objective was safety and tolerability, which has no formal efficacy test, so there is no met or missed result. More participants on sabirnetug than on placebo had at least one adverse event (56.3% vs 42.9%), and no deaths occurred. As an exploratory measure, amyloid plaque fell by about 25% and 20% over three months in the two highest multiple-dose groups. The figures come from the peer-reviewed report of the trial in the Journal of Prevention of Alzheimer's Disease. Registry: NCT04931459 | 1 | Incidence and Nature of Treatment-Related Adverse Events (AE) or Serious Adverse Events (SAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) (Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)); Change in Clinical Laboratory Tests (Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)); Changes in 12-Lead ECGs (Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)); Changes in the Columbia-Suicide Severity Rating Scale (C-SSRS) (Baseline up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)); Changes in Magnetic Resonance Imaging (MRI) (Baseline (predose) up to 20 weeks (SAD); 14, 18 or 28 weeks (MAD)) 2023-06-12 | Primary, safety and tolerability (no formal efficacy test): at least one treatment-emergent adverse event in 56.3% of sabirnetug vs 42.9% of placebo participants; no deaths. Exploratory, amyloid PET over three months: approximately 25% and 20% Centiloid reductions with sabirnetug 60 mg/kg every four weeks and 25 mg/kg every two weeks. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Amyloid-beta (monoclonal antibody) drugs
Donanemab, Lecanemab, Remternetug, Trontinemab, SHR-1707 and 4 more. Compare all 10 Amyloid-beta (monoclonal antibody) drugs
This mechanism is crowded: 9 other tracked programmes target it, 9 of them ahead of this one.
This drug's own stage for Alzheimer's Disease: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sabirnetug: this drug | Discontinued | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | not yet graded | Featured results are safety only in this race | |
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | not yet graded | No reviewed efficacy summary in this indication | |
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT05108922: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6) | |
| Donepezil (Aricept) | Approved | Small molecule | Acetylcholinesterase | Partial signal | NCT00630851: Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized). | |
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT01767311: ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. missed | |
| AR1001 | Phase 3 | Small molecule | PDE5 | Partial signal | NCT03625622: Primary (ADAS-Cog-13 at Week 26): no significant differences between treatment groups in the overall population; post-hoc monotherapy subgroup on AR1001 30 mg improved 4.019 points (p=0.012). missed | |
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | Partial signal | No reviewed efficacy summary in this indication | |
| Brexpiprazole (Rexulti) | Phase 3 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT01862640: Change in CMAI Total score from baseline to Week 12 vs placebo (Study 1 = NCT01862640): brexpiprazole 2mg/day adjusted mean difference -3.77 (95% CI -7.38 to -0.17), p=0.040; brexpiprazole 1mg/day 0.23 (95% CI -3.40 to 3.86), p=0.90 NCT03620981: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. (Baseline and 10 weeks first dose, on average 10 weeks): Brexpiprazole 1 mg -11.7 units on a scale (Standard Error 1.2) | Brexpiprazole 2 mg -15.2 units on a scale (Standard Error 1.05) vs Placebo -8 units on a scale (Standard Error 1.03) | |
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | Partial signal | NCT05686044: ADAS-Cog11 change at Week 12: -2.32 placebo vs -1.34 (7.5 mg), -3.01 (15 mg), and -2.24 (30 mg) buntanetap/Posiphen; ADCS-CGIC at Week 12: 3.58 placebo vs 3.96 (7.5 mg), 3.61 (15 mg), and 3.83 (30 mg). | |
| Hydromethylthionine Mesylate | Phase 3 | Small molecule | Tau aggregation; Acetylcholine | Partial signal | NCT03446001: Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control) (52 weeks): TRx0237 16 mg/Day 1.34 score on a scale (95% CI 0.32 to 2.36) vs Control 1.71 score on a scale (95% CI 0.69 to 2.73) NCT01689233: As-randomized primary comparison (100 mg vs 4 mg twice daily, the trial's pre-specified design): no significant difference on primary or secondary outcomes. Post-hoc modified-primary-outcome monotherapy cohort analysis: ADAS-cog effect size -3.14 (95% CI -5.32 to -0.97, p=0.0047) for 100 mg monotherapy (n=76) vs 4 mg as-randomized (n=388); -4.22 (95% CI -6.19 to -2.24, p<0.0001) for 4 mg monotherapy (n=79) vs 4 mg add-on (n=309) | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | Partial signal | NCT01872598: Co-primary endpoints at week 24, masitinib 4.5 mg/kg/day vs placebo, each tested at 2.5%: ADAS-cog difference -2.15 (97.5% CI -3.48 to -0.81), p<0.001 (met); ADCS-ADL difference +1.82 (97.5% CI -0.15 to 3.79), p=0.038 (not met at the 2.5% level) | |
| Masupirdine | Phase 3 | Small molecule | Serotonin 5-HT6 receptor | Partial signal | NCT02580305: ADAS-Cog 11 change from baseline at Week 26: placebo +2.6 (SE 0.5); masupirdine 50 mg +2.0 (SE 0.5), difference vs placebo -0.5 (95% CI -1.8, 0.7; P=.41); masupirdine 100 mg +2.5 (SE 0.5), difference vs placebo -0.1 (95% CI -1.4, 1.2; P=.90) missed | |
| MLC901 (NeuroAiD II) | Phase 3 | Botanical | Traditional Chinese medicine (multi-component) | not yet graded | No reviewed efficacy summary in this indication | |
| Remlifanserin | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Remternetug | Phase 3 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication | |
| Sodium Oligomannate | Phase 3 | Small molecule | Gut microbiome / neuroinflammation | Reliable signal | NCT02293915: Change in ADAS-cog12 from baseline to Week 36 (GV-971 minus placebo): -2.15 points (95% CI -3.07 to -1.23; p<0.0001; Cohen's d 0.53), favoring GV-971 | |
| Tertomotide | Phase 3 | Peptide | Telomerase (hTERT) | Partial signal | NCT05189210: 52주 차 ADAS-cog11의 최소제곱평균값 변화량은 GV1001 0.56mg과 1.12mg 투약군에서 각각 4.14점, 4.31점으로 위약군 4.30점 (LS-mean change in ADAS-cog11 at week 52: GV1001 0.56 mg 4.14 points, 1.12 mg 4.31 points, placebo 4.30 points; not statistically significant) missed | |
| Tricaprilin | Phase 3 | Small molecule | Ketone-body metabolism | Partial signal | NCT01741194: Change from baseline at 26 weeks, ADAS-Cog11 (APOE4 non-carriers): placebo (n=138) 0.0 vs AC-1204/tricaprilin (n=137) 0.6; LS mean difference -0.761, p=0.2458 (not significant) missed | |
| Trontinemab | Phase 3 | Multispecific antibody | Amyloid-beta (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| AGB101 | Phase 2/3 | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A), low-dose | Partial signal | NCT03486938: CDR-SB difference vs placebo -0.10 (95% CI -0.85 to 0.58), not significant missed | |
| Blarcamesine | Phase 2/3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | Partial signal | NCT03790709: Co-primary endpoints at 48 weeks: ADAS-Cog13 difference vs placebo -2.027 (95% CI -3.522 to -0.533; P = 0.008); ADCS-ADL difference 0.775 (95% CI -0.874 to 2.423; P = 0.357, not significant). missed | |
| Deramciclane | Phase 2/3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deraphan | Phase 2/3 | Small molecule | NMDA receptor / 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Emestedastat (Xanamem) | Phase 2/3 | Small molecule | 11-beta-HSD1 | Partial signal | NCT02727699: ADAS-Cog v14 (Baseline, Week 12): Xanamem™ -1.5 units on a scale (Standard Deviation 6.47) vs Placebo -0.7 units on a scale (Standard Deviation 6.65) | |
| Etalanetug | Phase 2/3 | Monoclonal antibody | Tau (monoclonal antibody) | Weak signal | Featured results are safety only in this race | |
| Nivegacetor | Phase 2/3 | Undisclosed | Gamma-secretase (modulator) | not yet graded | No reviewed efficacy summary in this indication | |
| PM012 | Phase 2/3 | Botanical | Traditional Chinese medicine (multi-component) | Partial signal | No reviewed efficacy summary in this indication | |
| T3D-959 | Phase 2/3 | Small molecule | PPAR delta/gamma | Partial signal | No reviewed efficacy summary in this indication | |
| 50561 | Phase 2 | Small molecule | RAC1 | Partial signal | No reviewed efficacy summary in this indication | |
| AADvac1 | Phase 2 | Vaccine | Tau | Weak signal | Featured results are safety only in this race | |
| ABvac40 | Phase 2 | Vaccine | Amyloid-beta (Aβx-40) | Partial signal | Featured results are non-efficacy and safety only in this race | |
| ACI-35.030 | Phase 2 | Vaccine | Tau | Partial signal | Featured results are safety only in this race | |
| AD04 | Phase 2 | Vaccine | Aluminium hydroxide (Alhydrogel) | not yet graded | No reviewed efficacy summary in this indication | |
| AstroStem | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | NCT03117738: ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7. | |
| AV-1959R | Phase 2 | Vaccine | Amyloid-beta | Weak signal | Featured results are safety only in this race | |
| Bepranemab | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | Partial signal | NCT04867616: Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. missed | |
| Betovumeline / Fesoterodine (ML-007C-MA) | Phase 2 | Small molecule | Muscarinic M1 and M4 receptors (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| BEY2153 | Phase 2 | Small molecule | APP/tau (translation) | Partial signal | No reviewed efficacy summary in this indication | |
| Cerebrolysin | Phase 2 | Peptide | Porcine brain-derived neuropeptide mixture (multi-target) | Partial signal | NCT00911807: Week 28 ADAS-COG+ change: -2.348 Cerebrolysin + donepezil, -1.711 Cerebrolysin, and -1.246 donepezil; overall p=0.6348. Cerebrolysin + donepezil vs donepezil: mean difference -1.080 (95% CI -3.324 to 1.163; p=0.3434). missed | |
| Deulumateperone | Phase 2 | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diranersen | Phase 2 | RNA / oligonucleotide | MAPT mRNA (RNAi/ASO) | Weak signal | NCT05399888: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. missed | |
| Edaravone (TTYP01) | Phase 2 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Enrupatinib | Phase 2 | Small molecule | CSF-1R | not yet graded | No reviewed efficacy summary in this indication | |
| HT-4253 | Phase 2 | Small molecule | LRRK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Laromestrocel (Lomecel-B) | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | Featured results are safety only in this race | |
| Lemborexant (Dayvigo) | Phase 2 | Small molecule | Orexin receptor (repositioned) | Partial signal | NCT03001557: 4-week actigraphy endpoints vs placebo: L5 (restlessness measure) significantly decreased at 2.5mg, 5mg and 15mg doses (all p<0.05); relative amplitude significantly improved at 5mg and 15mg (both p<0.05); mean duration of sleep bouts significantly improved at 5mg (p<0.01) and 15mg (p=0.002). | |
| Leronlimab | Phase 2 | Monoclonal antibody | CCR5 co-receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LHP588 | Phase 2 | Small molecule | Gingipain | not yet graded | No reviewed efficacy summary in this indication | |
| Lifonebart (VHB937) | Phase 2 | Monoclonal antibody | TREM2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mivelsiran | Phase 2 | RNA / oligonucleotide | APP mRNA (RNAi) | not yet graded | No reviewed efficacy summary in this indication | |
| MK-2214 | Phase 2 | Monoclonal antibody | Phospho-tau (pSer413) | Partial signal | Featured results are safety only in this race | |
| Moponetug | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| NTRX-07 | Phase 2 | Small molecule | CB2 receptor | Weak signal | Featured results are safety only in this race | |
| ONO-2020 | Phase 2 | Small molecule | Epigenetic regulation (target undisclosed) | not yet graded | No reviewed efficacy summary in this indication | |
| Pegipanermin | Phase 2 | Biologic (subtype unspecified) | Soluble TNF (selective) | Partial signal | NCT05318976: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) (24 Weeks): 1.0 mg/kg XPro1595 0.05 z-score (Standard Error 0.04) vs 1.0 mg/kg Placebo 0.07 z-score (Standard Error 0.05) missed | |
| PRI-002 | Phase 2 | Small molecule | Amyloid-beta-42 oligomerization | Partial signal | No reviewed efficacy summary in this indication | |
| RB-ADSC | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| RO7269162 | Phase 2 | Small molecule | Gamma-secretase | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448851 | Phase 2 | Small molecule | TREM2 | Weak signal | Featured results are safety only in this race | |
| Seltorexant | Phase 2 | Small molecule | Orexin-2 receptor (OX2R) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1707 | Phase 2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2 | Small molecule | Dendritic spine density | not yet graded | No reviewed efficacy summary in this indication | |
| Tisolagiline | Phase 2 | Small molecule | MAO-B | not yet graded | No reviewed efficacy summary in this indication | |
| TML-6 | Phase 2 | Small molecule | Autolysosome (multi-target curcumin analogue) | Weak signal | No reviewed efficacy summary in this indication | |
| Traneurocin | Phase 2 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| ABBV-1758 | Phase 1/2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| ALIA-1758 | Phase 1 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Weak signal | No reviewed efficacy summary in this indication | |
| CM383 | Phase 1 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Weak signal | No reviewed efficacy summary in this indication | |
| PMN310 | Phase 1 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 69 furthest-along competitors are listed; 53 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent